EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults

Ana Ávila, Mercedes Cao, Mario Espinosa, Joaquín Manrique, Enrique Morales

Frontiers in Medicine · 01.12.2023 · 10

DOI: 10.3389/fmed.2023.1264310 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Medicine, online erschienen am 01.12.2023. Verfasst von Ana Ávila und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Hospital Universitario Dr. Peset, Valencia, Spain. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite significant advances in therapeutic management of atypical hemolytic uremic syndrome (aHUS), guidelines are not timely updated and achieving a consensus on management recommendations remains a topic of ongoing discussion.

Methods

A Scientific Committee with five experts was set up. A literature review was conducted and publications addressing the classification of aHUS, patient profiles and therapeutic approach were selected. Recommendations were proposed at an initial meeting, evaluated through an online questionnaire and validated during a second meeting.

Results

Patients with confirmed or clear suspicion of aHUS should be treated with C5 inhibitors within 24 h of the diagnosis or suspicion of aHUS. Treatment monitoring and the decision to interrupt treatment should be individualised according to the risk of relapse and each patient’s evolution. aHUS with a genetic variant or associated with pregnancy should be treated for at least 6–12 months; de novo aHUS associated with kidney transplant until renal function is recovered and genetic variants are ruled out; aHUS associated with malignant hypertension until genetic variants are ruled out; aHUS associated with non-kidney transplant, autoimmune diseases, infection-or drug-induced until the thrombotic microangiopathy is resolved. Patients with a high risk of relapse should be treated for longer than 6–12 months.

Conclusion

These recommendations provides physicians who are not familiar with the disease with recommendations for the management of aHUS in adults. The experts who participated advocate early treatment, maintenance for at least 6–12 months and treatment interruption guided by genetic background, trigger factors, risk of relapse and evolution.

Schlagwörter

Stichwörter der Autor:innen

C5 inhibitoratypical hemolytic uremic syndromeearly treatment initiationthrombotic microangiopathytreatment interruption

Autor:innen und Institutionen

  • Department of Nephrology, Hospital Universitario Dr. Peset, Valencia, Spain.
  • Department of Nephrology, Hospital Universitario A Coruña, A Coruña, Spain.
  • Department of Nephrology, Hospital Universitario Reina Sofía, Córdoba, Spain.
  • Department of Nephrology, Complejo Hospitalario de Navarra, Pamplona, Spain.
  • Department of Nephrology, Hospital Universitario 12 de Octubre, Madrid, Spain.

Zitieren

APA

Ávila, A., Cao, M., Espinosa, M., Manrique, J., & Morales, E. (2023). Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults. Frontiers in Medicine, 10. https://doi.org/10.3389/fmed.2023.1264310

Vancouver

Ávila A, Cao M, Espinosa M, Manrique J, Morales E. Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults. Frontiers in Medicine. 2023;10. doi:10.3389/fmed.2023.1264310

BibTeX
@article{vila2023,
  author = {Ávila, Ana and Cao, Mercedes and Espinosa, Mario and Manrique, Joaquín and Morales, Enrique},
  title = {Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults},
  journal = {Frontiers in Medicine},
  year = {2023},
  volume = {10},
  doi = {10.3389/fmed.2023.1264310}
}
Kostenlos starten →